Dendritic cell immunotherapy for breast cancer

Bibliography

• LEWISON EF: The surgical treatment of breast cancer: an historical and collective review. Surgery (1953) 34(5):904-953.
   PubMed Web of Science ®Google Scholar
• FISHER B, RAVDIN RG, AUSMAN RK et al.: Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation. Ann. Surg. (1968) 168(3):337-356.
   PubMed Web of Science ®Google Scholar
• FLETCHER GH: Local results of irradiation in the primary management of localized breast cancer. Cancer (1972) 29(3):545-551.
   PubMed Web of Science ®Google Scholar
• THERASSE P, PICCART M, VAN DE VELDE CJ, JASSEM J: The EORTC Breast Cancer Group: 40 years of research contributing to improve breast cancer management. Eur. J. Cancer (2002) 38(Suppl. 4):S39-S43.
   Google Scholar
• LESPAGNARD L, GANCBERG D, ROUAS G et al.: Tumor-infiltrating dendritic cells in adenocarcinomas of the breast: a study of 143 neoplasms with a correlation to usual prognostic factors and to clinical outcome. Int. J. Cancer (1999) 84(3):309-314.
   PubMed Web of Science ®Google Scholar
• IWAMOTO M, SHINOHARA H, MIYAMOTO A et al.: Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int. J. Cancer (2003) 104(1):92-97.
   PubMed Web of Science ®Google Scholar
• BELL D, CHOMARAT P, BROYLES D et al.: In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J. Exp. Med. (1999) 190(10):1417-1426.
   PubMed Web of Science ®Google Scholar
• GABRILOVICH DI, CORAK J, CIERNIK IF, KAVANAUGH D, CARBONE DP: Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin. Cancer Res. (1997) 3(3):483-490.
   PubMed Web of Science ®Google Scholar
• DELLA BELLA S, GENNARO M, VACCARI M et al.: Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br. J. Cancer (2003) 89(8):1463-1472.
   PubMed Web of Science ®Google Scholar
• PINZON-CHARRY A, MAXWELL T, MCGUCKIN MA et al.: Spontaneous apoptosis of blood dendritic cells in patients with breast cancer. Breast Cancer Res. (2006) 8:R5.
   PubMed Web of Science ®Google Scholar
• PEDERSEN AE, THORN M, GAD M et al.: Phenotypic and functional characterization of clinical grade dendritic cells generated from patients with advanced breast cancer for therapeutic vaccination. Scand. J. Immunol. (2005) 61(2):147-156.
   PubMed Web of Science ®Google Scholar
• SCANLAN MJ, JAGER D: Challenges to the development of antigen-specific breast cancer vaccines. Breast Cancer Res. (2001) 3(2):95-98.
   PubMed Web of Science ®Google Scholar
• HADDEN JW: The immunology and immunotherapy of breast cancer: an update. Int. J. Immunopharmacol. (1999) 21(2):79-101.
   PubMed Web of Science ®Google Scholar
• FISHER B: Laboratory and clinical research in breast cancer-a personal adventure: the David A. Karnofsky memorial lecture. Cancer Res. (1980) 40(11):3863-3874.
   PubMed Web of Science ®Google Scholar
• FISHER ER, GREGORIO R, REDMOND C, DEKKER A, FISHER B: Pathologic findings from the national surgical adjuvant breast project (protocol no. 4). II. The significance of regional node histology other than sinus histiocytosis in invasive mammary cancer. Am. J. Clin. Pathol. (1976) 65(1):21-30.
   PubMed Web of Science ®Google Scholar
• MENARD S, TOMASIC G, CASALINI P et al.: Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin. Cancer Res. (1997) 3(5):817-819.
   PubMed Web of Science ®Google Scholar
• BAXEVANIS CN, DEDOUSSIS GV, PAPADOPOULOS NG et al.: Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer. Cancer (1994) 74(4):1275-1282.
   PubMed Web of Science ®Google Scholar
• DISIS ML, CALENOFF E, MCLAUGHLIN G et al.: Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res. (1994) 54(1):16-20.
   PubMed Web of Science ®Google Scholar
• JEROME KR, BARND DL, BENDT KM et al.: Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res. (1991) 51(11):2908-2916.
   PubMed Web of Science ®Google Scholar
• TUTTLE TM, ANDERSON BW, THOMPSON WE et al.: Proliferative and cytokine responses to class II HER-2/neu-associated peptides in breast cancer patients. Clin. Cancer Res. (1998) 4(8):2015-2024.
   PubMed Web of Science ®Google Scholar
• SOTIROPOULOU PA, PEREZ SA, VOELTER V et al.: Natural CD8+ T-cell responses against MHC class I epitopes of the HER-2/neu oncoprotein in patients with epithelial tumors. Cancer Immunol. Immunother. (2003) 52(12):771-779.
   PubMed Web of Science ®Google Scholar
• FEUERER M, ROCHA M, BAI L et al.: Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients. Int. J. Cancer (2001) 92(1):96-105.
   PubMed Web of Science ®Google Scholar
• VON MENSDORFF-POUILLY S, VERSTRAETEN AA, KENEMANS P et al.: Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J. Clin. Oncol. (2000) 18(3):574-583.
   PubMed Web of Science ®Google Scholar
• NISTICO P, MOTTOLESE M, CASCIOLI S et al.: Host immunosurveillance contributes to the control of erbB-2 overexpression in HLA-A2-breast-cancer patients. Int. J. Cancer (1999) 84(6):598-603.
   PubMed Web of Science ®Google Scholar
• CAMP BJ, DYHRMAN ST, MEMOLI VA, MOTT LA, BARTH RJ JR: in situ cytokine production by breast cancer tumor-infiltrating lymphocytes. Ann. Surg. Oncol. (1996) 3(2):176-184.
   PubMed Web of Science ®Google Scholar
• VENETSANAKOS E, BECKMAN I, BRADLEY J, SKINNER JM: High incidence of interleukin 10 mRNA but not interleukin 2 mRNA detected in human breast tumours. Br. J. Cancer (1997) 75(12):1826-1830.
   PubMed Web of Science ®Google Scholar
• LIYANAGE UK, MOORE TT, JOO HG et al.: Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. (2002) 169(5):2756-2761.
   PubMed Web of Science ®Google Scholar
• WOLF AM, WOLF D, STEURER M et al.: Increase of regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res. (2003) 9(2):606-612.
   PubMed Web of Science ®Google Scholar
• LEONG PP, MOHAMMAD R, IBRAHIM N et al.: Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast. Immunol. Lett. (2006) 102(2):229-236.
   PubMed Web of Science ®Google Scholar
• GUTIERREZ LS, ELIZA M, NIVEN-FAIRCHILD T, NAFTOLIN F, MOR G: The Fas/Fas-ligand system: a mechanism for immune evasion in human breast carcinomas. Breast Cancer Res. Treat. (1999) 54(3):245-253.
   PubMed Web of Science ®Google Scholar
• SHEEN-CHEN SM, CHEN HS, ENG HL, CHEN WJ: Circulating soluble Fas in patients with breast cancer. World J. Surg. (2003) 27(1):10-13.
   PubMed Web of Science ®Google Scholar
• PINZON-CHARRY A, MAXWELL T, LOPEZ JA: Dendritic cell dysfunction in cancer: A mechanism for immunosuppression. Immunol. Cell Biol. (2005) 83(5):451-461.
   PubMed Web of Science ®Google Scholar
• LISSONI P, VIGORE L, FERRANTI R et al.: Circulating dendritic cells in early and advanced cancer patients: diminished percent in the metastatic disease. J. Biol. Regul. Homeost. Agents (1999) 13(4):216-219.
   PubMed Web of Science ®Google Scholar
• SATTHAPORN S, ROBINS A, VASSANASIRI W et al.: Dendritic cells are dysfunctional in patients with operable breast cancer. Cancer Immunol. Immunother. (2004) 53(6):510-518.
   PubMed Web of Science ®Google Scholar
• PINZON-CHARRY A, HO C, LAHERTY R et al.: A population of HLA-DR+ immature cells accumulate in the blood dendritic cell compartment of patients with different types of cancer. Neoplasia (2005) 7(12):1123-1132.
   PubMed Web of Science ®Google Scholar
• PINZON-CHARRY A, MAXWELL T, PRATO S et al.: HLA-DR+ immature cells exhibit reduced antigen presenting cell function but respond to CD40 stimulation. Neoplasia (2005) 7(12):1112-1122.
   PubMed Web of Science ®Google Scholar
• BARRATT-BOYES SM: Making the most of mucin: a novel target for tumor immunotherapy. Cancer Immunol. Immunother. (1996) 43(3):142-151.
   PubMed Web of Science ®Google Scholar
• BALDUS SE, WIENAND JR, WERNER JP et al.: Expression of MUC1, MUC2 and oligosaccharide epitopes in breast cancer: prognostic significance of a sialylated MUC1 epitope. Int. J. Oncol. (2005) 27(5):1289-1297.
   PubMed Web of Science ®Google Scholar
• KOTERA Y, FONTENOT JD, PECHER G, METZGAR RS, FINN OJ: Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res. (1994) 54(11):2856-2860.
   PubMed Web of Science ®Google Scholar
• FEUERER M, BECKHOVE P, BAI L et al.: Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat. Med. (2001) 7(4):452-458.
   PubMed Web of Science ®Google Scholar
• BECKHOVE P, FEUERER M, DOLENC M et al.: Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors. J. Clin. Invest. (2004) 114(1):67-76.
   PubMed Web of Science ®Google Scholar
• SLAMON DJ, LEYLAND-JONES B, SHAK S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. (2001) 344(11):783-792.
   PubMed Web of Science ®Google Scholar
• SLAMON DJ, CLARK GM, WONG SG et al.: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 235(4785):177-182.
   PubMed Web of Science ®Google Scholar
• KNUTSON KL, SCHIFFMAN K, DISIS ML: Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J. Clin. Invest. (2001) 107(4):477-484.
   PubMed Web of Science ®Google Scholar
• KIRKPATRICK KL, CLARK G, GHILCHICK M, NEWBOLD RF, MOKBEL K: hTERT mRNA expression correlates with telomerase activity in human breast cancer. Eur. J. Surg. Oncol. (2003) 29(4):321-326.
   PubMed Web of Science ®Google Scholar
• POREMBA C, HEINE B, DIALLO R et al.: Telomerase as a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR. J. Pathol. (2002) 198(2):181-189.
   PubMed Web of Science ®Google Scholar
• AMARNATH SM, DYER CE, RAMESH A et al.: In vitro quantification of the cytotoxic T lymphocyte response against human telomerase reverse transcriptase in breast cancer. Int. J. Oncol. (2004) 25(1):211-217.
   PubMed Web of Science ®Google Scholar
• RUNNEBAUM IB, NAGARAJAN M, BOWMAN M, SOTO D, SUKUMAR S: Mutations in p53 as potential molecular markers for human breast cancer. Proc. Natl. Acad. Sci. USA (1991) 88(23):10657-10661.
   PubMed Web of Science ®Google Scholar
• NIKITINA EY, CLARK JI, VAN BEYNEN J et al.: Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients. Clin. Cancer Res. (2001) 7(1):127-135.
   PubMed Web of Science ®Google Scholar
• NASU S, YAGIHASHI A, IZAWA A et al.: Survivin mRNA expression in patients with breast cancer. Anticancer Res. (2002) 22(3):1839-1843.
   PubMed Web of Science ®Google Scholar
• ANDERSEN MH, PEDERSEN LO, CAPELLER B et al.: Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res. (2001) 61(16):5964-5968.
   PubMed Web of Science ®Google Scholar
• LIU Y, CHIRIVA-INTERNATI M, YOU C et al.: Use and specificity of breast cancer antigen/milk protein BA46 for generating anti-self-cytotoxic T lymphocytes by recombinant adeno-associated virus-based gene loading of dendritic cells. Cancer Gene Ther. (2005) 12(3):304-312.
   PubMed Web of Science ®Google Scholar
• KIM DK, LEE TV, CASTILLEJA A et al.: Folate binding protein peptide 191-199 presented on dendritic cells can stimulate CTL from ovarian and breast cancer patients. Anticancer Res. (1999) 19(4B):2907-2916.
   PubMed Web of Science ®Google Scholar
• FIGDOR CG, DE VRIES IJ, LESTERHUIS WJ, MELIEF CJ: Dendritic cell immunotherapy: mapping the way. Nat. Med. (2004) 10(5):475-480.
   PubMed Web of Science ®Google Scholar
• LOPEZ JA, HART DN: Current issues in dendritic cell cancer immunotherapy. Curr. Opin. Mol. Ther. (2002) 4(1):54-63.
   PubMed Web of Science ®Google Scholar
• EDGHILL-SMITH Y, GOLDING H, MANISCHEWITZ J et al.: Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat. Med. (2005) 11(7):740-747.
   PubMed Web of Science ®Google Scholar
• OVERWIJK WW, THEORET MR, FINKELSTEIN SE et al.: Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. (2003) 198(4):569-580.
   PubMed Web of Science ®Google Scholar
• YU P, ROWLEY DA, FU YX, SCHREIBER H: The role of stroma in immune recognition and destruction of well-established solid tumors. Curr. Opin. Immunol. (2006) 18(2):226-231.
   PubMed Web of Science ®Google Scholar
• RIDGWAY D: The first 1000 dendritic cell vaccinees. Cancer Invest. (2003) 21(6):873-886.
   PubMed Web of Science ®Google Scholar
• YU P, LEE Y, LIU W et al.: Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J. Exp. Med. (2005) 201(5):779-791.
   PubMed Web of Science ®Google Scholar
• MULLER AJ, DUHADAWAY JB, DONOVER PS, SUTANTO-WARD E, PRENDERGAST GC: Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med. (2005) 11(3):312-319.
   PubMed Web of Science ®Google Scholar
• DANNULL J, SU Z, RIZZIERI D et al.: Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. (2005) 115(12):3623-3633.
   PubMed Web of Science ®Google Scholar
• PHAN GQ, YANG JC, SHERRY RM et al.: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA (2003) 100(14):8372-8377.
   PubMed Web of Science ®Google Scholar
• KICHLER-LAKOMY C, BUDINSKY AC, WOLFRAM R et al.: Deficiences in phenotype expression and function of dentritic cells from patients with early breast cancer. Eur. J. Med. Res. (2006) 11(1):7-12.
   PubMed Web of Science ®Google Scholar
• MATTES J, HULETT M, XIE W et al.: Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J. Exp. Med. (2003) 197(3):387-393.
   PubMed Web of Science ®Google Scholar
• GILBOA E: The promise of cancer vaccines. Nat. Rev. Cancer (2004) 4(5):401-411.
   PubMed Web of Science ®Google Scholar
• ELLIOTT SL, PYE S, LE T et al.: Peptide based cytotoxic T-cell vaccines; delivery of multiple epitopes, help, memory and problems. Vaccine (1999) 17(15-16):2009-2019.
   PubMed Web of Science ®Google Scholar
• FUCHS EJ, MATZINGER P: Is cancer dangerous to the immune system? Semin. Immunol. (1996) 8(5):271-280.
   PubMedGoogle Scholar
• YANG J, HUCK SP, MCHUGH RS, HERMANS IF, RONCHESE F: Perforin-dependent elimination of dendritic cells regulates the expansion of antigen-specific CD8+ T cells in vivo. Proc. Natl. Acad. Sci. USA (2006) 103(1):147-152.
   PubMed Web of Science ®Google Scholar
• FAY JW, PALUCKA AK, PACZESNY S et al.: Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells. Cancer Immunol. Immunother. (2005):1-10.
   Web of Science ®Google Scholar
• NESTLE FO, ALIJAGIC S, GILLIET M et al.: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. (1998) 4(3):328-332.
   PubMed Web of Science ®Google Scholar
• O’ROURKE MG, JOHNSON M, LANAGAN C et al.: Durable complete clinical responses in a Phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol. Immunother. (2003) 52(6):387-395.
   PubMed Web of Science ®Google Scholar
• BROSSART P, WIRTHS S, STUHLER G et al.: Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood (2000) 96(9):3102-3108.
   PubMed Web of Science ®Google Scholar
• GERMEAU C, MA W, SCHIAVETTI F et al.: High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J. Exp. Med. (2005) 201(2):241-248.
   PubMed Web of Science ®Google Scholar
• SCHREIBER H, WU TH, NACHMAN J, KAST WM: Immunodominance and tumor escape. Semin. Cancer Biol. (2002) 12(1):25-31.
   PubMed Web of Science ®Google Scholar
• THURNER B, HAENDLE I, RODER C et al.: Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. (1999) 190(11):1669-1678.
   PubMed Web of Science ®Google Scholar
• VAN DER BRUGGEN P, TRAVERSARI C, CHOMEZ P et al.: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 254:1643.
   PubMed Web of Science ®Google Scholar
• WOLFEL T, HAUER M, SCHNEIDER J et al.: A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science (1995) 269(5228):1281-1284.
   PubMed Web of Science ®Google Scholar
• KHONG HT, RESTIFO NP: Natural selection of tumor variants in the generation of ‘tumor escape’ phenotypes. Nat. Immun. (2002) 3(11):999-1005.
   Google Scholar
• DONTU G, ABDALLAH WM, FOLEY JM et al.: In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. (2003) 17(10):1253-1270.
   PubMed Web of Science ®Google Scholar
• REYNOLDS BA, WEISS S: Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science (1992) 255(5052):1707-1710.
   PubMed Web of Science ®Google Scholar
• GILBOA E: The risk of autoimmunity associated with tumor immunotherapy. Nat. Immun. (2001) 2(9):789-792.
   Google Scholar
• DEES EC, MCKINNON KP, KUHNS JJ et al.: Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer. Cancer Immunol. Immunother. (2004) 53(9):777-785.
   PubMed Web of Science ®Google Scholar
• GONG J, AVIGAN D, CHEN D et al.: Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc. Natl. Acad. Sci. USA (2000) 97(6):2715-2718.
   PubMed Web of Science ®Google Scholar
• NEIDHARDT-BERARD EM, BERARD F, BANCHEREAU J, PALUCKA AK: Dendritic cells loaded with killed breast cancer cells induce differentiation of tumor-specific cytotoxic T lymphocytes. Breast Cancer Res. (2004) 6(4):R322-R328.
   PubMed Web of Science ®Google Scholar
• TRIOZZI PL, KHURRAM R, ALDRICH WA et al.: Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer (2000) 89(12):2646-2654.
   PubMed Web of Science ®Google Scholar
• SVANE IM, PEDERSEN AE, JOHNSEN HE et al.: Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a Phase I study. Cancer Immunol. Immunother. (2004) 53(7):633-641.
   PubMed Web of Science ®Google Scholar
• DHODAPKAR MV, STEINMAN RM, KRASOVSKY J, MUNZ C, BHARDWAJ N: Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. (2001) 193(2):233-238.
   PubMed Web of Science ®Google Scholar
• PECHER G, HARING A, KAISER L, THIEL E: Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a Phase I/II clinical trial. Cancer Immunol. Immunother. (2002) 51(11-12):669-673.
   PubMed Web of Science ®Google Scholar
• LOVELAND BE, ZHAO A, WHITE S et al.: Mannan-MUC1-pulsed dendritic cell immunotherapy: a Phase I trial in patients with adenocarcinoma. Clin. Cancer Res. (2006) 12(3 Pt 1):869-877.
   PubMed Web of Science ®Google Scholar
• MEYER ZUM BUSCHENFELDE C, METZGER J, HERMANN C et al.: The generation of both t killer and th cell clones specific for the tumor-associated antigen her2 using retrovirally transduced dendritic cells. J. Immunol. (2001) 167(3):1712-1719.
   PubMed Web of Science ®Google Scholar
• SAKAI Y, MORRISON BJ, BURKE JD et al.: Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice. Cancer Res. (2004) 64(21):8022-8028.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI T, SHINOHARA H, TOYODA M, IWAMOTO S, TANIGAWA N: Regression of lymph node metastases by immunotherapy using autologous breast tumor-lysate pulsed dendritic cells: report of a case. Surg. Today (2001) 31(6):513-516.
   PubMed Web of Science ®Google Scholar
• AVIGAN D, VASIR B, GONG J et al.: Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin. Cancer Res. (2004) 10(14):4699-4708.
   PubMed Web of Science ®Google Scholar
• SU Z, DANNULL J, HEISER A et al.: Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. (2003) 63(9):2127-2133.
   PubMed Web of Science ®Google Scholar
• LAKE RA, ROBINSON BW: Immunotherapy and chemotherapy-a practical partnership. Nat. Rev. Cancer (2005) 5(5):397-405.
   PubMed Web of Science ®Google Scholar
• EMENS LA, REILLY RT, JAFFEE EM: Augmenting the potency of breast cancer vaccines: combined modality immunotherapy. Breast Dis. (2004) 20:13-24.
   PubMedGoogle Scholar
• YU B, KUSMARTSEV S, CHENG F et al.: Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer. Clin. Cancer Res. (2003) 9(1):285-294.
   PubMed Web of Science ®Google Scholar
• EMENS LA, JAFFEE EM: Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res. (2005) 65(18):8059-8064.
   PubMed Web of Science ®Google Scholar
• WHEELER CJ, DAS A, LIU G, YU JS, BLACK KL: Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin. Cancer Res. (2004) 10(16):5316-5326.
   PubMed Web of Science ®Google Scholar
• GRUNEBACH F, MULLER MR, BROSSART P: New developments in dendritic cell-based vaccinations: RNA translated into clinics. Cancer Immunol. Immunother. (2005) 54(6):517-525.
   PubMed Web of Science ®Google Scholar
• HEISER A, MAURICE MA, YANCEY DR et al.: Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J. Immunol. (2001) 166(5):2953-2960.
   PubMed Web of Science ®Google Scholar
• AL-HAJJ M, CLARKE MF: Self-renewal and solid tumor stem cells. Oncogene (2004) 23(43):7274-7282.
   PubMed Web of Science ®Google Scholar
• STINGL J, EIREW P, RICKETSON I et al.: Purification and unique properties of mammary epithelial stem cells. Nature (2006) 439(7079):993-997.
   PubMed Web of Science ®Google Scholar
• PONTI D, COSTA A, ZAFFARONI N et al.: Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. (2005) 65(13):5506-5511.
   PubMed Web of Science ®Google Scholar
• SMALLEY M, ASHWORTH A: Stem cells and breast cancer: a field in transit. Nat. Rev. Cancer (2003) 3(11):832-844.
   PubMed Web of Science ®Google Scholar
• HODGE JW: Carcinoembryonic antigen as a target for cancer vaccines. Cancer Immunol. Immunother. (1996) 43(3):127-134.
   PubMed Web of Science ®Google Scholar
• JAGER D, STOCKERT E, GURE AO et al.: Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library. Cancer Res. (2001) 61(5):2055-2061.
   PubMed Web of Science ®Google Scholar
• SAHIN U, TURECI O, CHEN YT et al.: Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: basis for polyvalent CT vaccine strategies. Int. J. Cancer (1998) 78(3):387-389.
   PubMed Web of Science ®Google Scholar
• CHEN YT, GURE AO, TSANG S et al.: Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc. Natl. Acad. Sci. USA (1998) 95(12):6919-6923.
   PubMed Web of Science ®Google Scholar
• SCANLAN MJ, GOUT I, GORDON CM et al.: Humoral immunity to human breast cancer: antigen definition and quantitative analysis of mRNA expression. Cancer Immun. (2001) 1:4.
   PubMedGoogle Scholar
• WATSON MA, FLEMING TP: Mammaglobin, a mammary-specific member of the uteroglobin gene family, is overexpressed in human breast cancer. Cancer Res. (1996) 56(4):860-865.
   PubMed Web of Science ®Google Scholar
• LAROCCA D, PETERSON JA, URREA R et al.: A Mr 46,000 human milk fat globule protein that is highly expressed in human breast tumors contains Factor VIII-like domains. Cancer Res. (1991) 51(18):4994-4998.
   PubMed Web of Science ®Google Scholar
• VONDERHEIDE RH, DOMCHEK SM, SCHULTZE JL et al.: Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin. Cancer Res. (2004) 10(3):828-839.
   PubMed Web of Science ®Google Scholar